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Purpose: The objective was to expand on prior work by developing and validating a new 
algorithm to identify multiple myeloma (MM) patients in administrative claims.
Methods: Two files were constructed to select MM cases from MarketScan Oncology 
Electronic Medical Records (EMR) and controls from the MarketScan Primary Care EMR 
during January 1, 2000–March 31, 2014. Patients were linked to MarketScan claims 
databases, and files were merged. Eligible cases were age ≥18, had a diagnosis and 
visit for MM in the Oncology EMR, and were continuously enrolled in claims for ≥90 days 
preceding and ≥30 days after diagnosis. Controls were age ≥18, had ≥12 months of 
overlap in claims enrollment (observation period) in the Primary Care EMR and ≥1 claim 
with an ICD-9-CM diagnosis code of MM (203.0×) during that time. Controls were 
excluded if they had chemotherapy; stem cell transplant; or text documentation of MM 
in the EMR during the observation period. A split sample was used to develop and 
validate algorithms. A maximum of 180 days prior to and following each MM diagnosis 
was used to identify events in the diagnostic process. Of 20 algorithms explored, the 
baseline algorithm of 2 MM diagnoses and the 3 best performing were validated. Values 
for sensitivity, specificity, and positive predictive value (PPV) were calculated.
Conclusion: Three claims-based algorithms were validated with ~10% improvement in 
PPV (87–94%) over prior work (81%) and the baseline algorithm (76%) and can be con-
sidered for future research. Consistent with prior work, it was found that MM diagnoses 
before and after tests were needed.
Keywords: multiple myeloma, administrative claims, electronic medical records, algorithm
INtRodUCtIoN
Cancer research using secondary data sources requires accurate identification of patients with 
specific cancer diagnoses. A recent review of cancer studies using secondary data sources, found 
36% used just a single claim with a cancer diagnosis to identify the study sample while only 6.5% 
used a validated algorithm (1). The diagnostic process for cancer involves many laboratory blood 
tests, imaging, and surgical biopsies, therefore just one or two health service claims with the cancer 
diagnosis code may not be sufficient for correct identification of a cancer population.
Multiple myeloma (MM) is a hematologic cancer that leads to the accumulation of malignant 
plasma cells in the bone marrow and over production of monoclonal proteins in the serum or 
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urine  (2). It is the second most common hematologic malig-
nancy, accounting for 12% of hematologic cancers worldwide 
(3). Recent advances in treatment have extended survival 
but prognosis is still poor with an overall median survival of 
4–7 years from initial diagnosis (4).
Patients with MM are diagnosed by pathological changes in 
the blood and symptoms of hypercalcemia, renal dysfunction, 
anemia, and bone pain from lesions (referred to as the CRAB 
criteria) (5–7). MM is part of a spectrum of monoclonal plasma 
cell disorders, leading to increased complexity in diagnosing the 
disease. Patients with suspected MM are typically identified as 
having monoclonal gammopathy of undetermined significance 
(MGUS), smoldering MM (SMM), or active MM, with addi-
tional testing needed to determine a definitive diagnosis (8–12). 
MGUS, defined as having less than 10% plasma cells in the bone 
marrow and a monoclonal protein level less than 3 g/dL (5, 8), 
represents the least pathologically advanced disorder along this 
spectrum, is asymptomatic, and requires no therapeutic inter-
vention. Patients with MGUS progress to active MM at a rate 
of ~0.26–12% per year (depending on tumor type) and many 
patients never progress (9, 10, 13).
Smoldering MM, often referred to as “early MM,” has a risk 
of progressing of 10% per year for the first 5 years, 3% per year 
for the next 5 years, and 1–2% per year for the next 10 years 
(11, 12). Patients with SMM have an excess of monoclonal 
protein in the blood and urine but are asymptomatic. Definitive 
diagnosis of SMM includes a monoclonal protein level of at least 
3 g/dL or the proportion of plasma cells in the bone marrow 
is at least 10% (5, 8). SMM patients are monitored for disease 
progression with treatment initiated only after progression. 
However, recent literature suggests earlier treatment may be 
beneficial (8, 14).
Given the complexity of diagnosing MM, it is possible that 
patients may be misdiagnosed during the diagnostic process. 
MM diagnoses can appear on diagnostic claims to rule out 
disease, can result in misclassification of individuals as having 
MM, when they actually have MGUS or a different cancer. Prior 
research in MM using claims data has relied on identifying a 
treated population (15–17). While the strategy of requiring both 
appropriate diagnosis codes and disease-specific treatments can 
better identify true cases, this approach excludes the untreated 
population from research questions. Recent work to develop and 
validate an algorithm identifying MM patients in administrative 
claims used the SEER Tumor Registry (18). At least two diagnoses 
before and after a diagnostic procedure code within 90 days were 
needed to achieve a positive predictive value (PPV) of 81% and a 
sensitivity of 73% (18). The primary objective of this analysis was 
to expand and improve on prior work by developing and validat-
ing algorithms with better PPV and sensitivity. The secondary 
objective was to determine if an algorithm could be created to 
identify patients with SMM or untreated MM.
Methods
data sources
This study utilized MM cases and controls from four Marketscan® 
databases: two MarketScan Electronic Medical Records (EMR) 
Databases (Oncology EMR and Primary Care EMR) and two 
MarketScan administrative claims databases (Commercial 
and Medicare Supplemental). The Commercial and Medicare 
Supplemental claims databases includes employer- and health 
plan-sourced medical and outpatient pharmacy data for ~41 
million enrollees per year, linked by a unique blinded identifier 
across the continuum of care. All databases were de-identified in 
compliance with Health Insurance Portability and Accountability 
Act (HIPAA) regulations. Patients eligible for the analysis were 
present in the Claims-Oncology EMR Linked Dataset or the 
Claims-Primary Care EMR Linked Dataset, which combine 
the clinical detail from EMR and the claims-level details of all 
provider visits, diagnoses, procedures, and medications needed 
for algorithm development.
Patient selection
As an initial step, two separate files were constructed to select 
cases (true MM patients; “gold standard”) from the MarketScan 
Oncology EMR database linked to the MarketScan Commercial 
and Medicare claims databases and controls (patients known to 
be absent of MM) from the MarketScan Primary Care EMR data-
base linked to the MarketScan claims databases during January 1, 
2000–March 31, 2014 (study period).
Inclusion criteria for MM cases were, age 18 years or older, 
have a diagnosis and a clinic visit date for MM in the Oncology 
EMR and be continuously enrolled in the claims database for at 
least 90 days preceding and 30 days following the EMR diagnosis. 
MM cases were identified as incident if there were no claims for 
chemotherapy treatment or administration associated with an 
MM diagnosis prior to the EMR date of diagnosis.
Inclusion criteria for MM controls were, age 18 years or older, 
at least 12 months of overlap in enrollment (observation period) 
in both the Primary Care EMR and claims and have at least 1 
claim with an ICD-9-CM diagnosis code of MM (203.0×) dur-
ing that time. To ensure, controls did not have MM during the 
observation period, patients meeting any of the following criteria 
were excluded: (1) a chemotherapy treatment or administration 
claim associated with an MM diagnosis, (2) a stem cell transplant 
procedure claim, and (3) evidence of MM in the primary care 
EMR identified through review of all primary care records with 
any text documentation of MM. Following selection of cases and 
controls, the two files were merged for algorithm development. 
Figure 1 depicts the case and control selection process.
Algorithm development
The file was randomly split in half with the first half used to 
develop the algorithm (development sample) and the second 
half to validate the algorithm (validation sample). A panel file 
was constructed to test algorithms on all MM diagnoses in the 
claims data for cases and controls captured during the study 
period. A diagnosis was eligible for inclusion in the panel as an 
index event if there was continuous enrollment for a minimum of 
90 days prior and 30 days following the diagnosis. A maximum of 
180 days before and after each eligible diagnosis was used to iden-
tify tests, treatments, and symptoms used in the MM diagnostic 
process. Figure 2 portrays the process of splitting the sample and 
identification of eligible claims diagnoses.
FIgURe 1 | Case and control selection.
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All variables used in the algorithm were claims based and 
identified using enrollment records, service dates, International 
Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) codes, Current Procedural Technology 4th edition 
(CPT-4®) codes, Healthcare Common Procedure Coding System 
(HCPCS) codes, and National Drug Codes (NDCs). Using the 
development sample, each MM diagnosis was labeled first as a 
case or a control. Diagnoses from cases were then divided further 
to analyze untreated and treated patients. Data were explored for 
differences in patterns (combinations, timing, and sequences of 
events) between cases and controls through descriptive analysis 
and review of patient profiles. Table 1 contains the average annual 
number of tests, MM diagnoses, and days of chemotherapy treat-
ment per patient tabulated by MM status and the presence or 
absence of MM chemotherapy treatment in the development 
sample. There were no notable patterns in the development 
sample that differentiated untreated cases from controls.
More than 20 different algorithms were created in the develop-
ment sample and applied to both the total population and then 
separately to the untreated cases. Algorithms were derived using 
clinical expertise in the MM disease area and by review of patterns 
in the descriptive results. The best performing algorithms (i.e., 
highest specificity and sensitivity) in the development sample were 
applied to the validation sample where final values for sensitivity, 
specificity, and PPV were calculated. Sensitivity and specificity 
were calculated directly using the algorithm results. Since the 
cases and controls were identified from two different databases, 
the PPV could not be calculated directly, but was derived applying 
the algorithm to a large general population claims (Marketscan) 
database and identifying the percent with a MM diagnosis flagged. 
This percentage was used in the following formula with the sen-
sitivity and specificity of the algorithm, to calculate the PPV in 
MarketScan [PPV = (sensitivity × (% flagged + specificity − 1))/
(% flagged × (sensitivity + specificity − 1))]. The derivation of the 
formula can be found in Supplementary Material.
ResULts
From the 336 cases and the 683 controls who comprised the 
validation sample, controls had 3,185 and cases had 22,419 (3,442 
untreated; 18,977 treated) MM diagnoses available for evaluation. 
Demographic characteristics were similar for cases and controls 
with the mean age ~65 years and even gender and payer distribu-
tion (~50% male and ~50% commercially insured).
tAbLe 1 | Average annual number of diagnostic tests, MM diagnoses, and days of chemotherapy treatment per patient tabulated by true MM status and 
presence or absence of chemotherapy treatment using development sample.
Patient 
status
N Protein 
electrophoresis
Quantitative 
immunoglobulin
serum free 
light chain
serum 
albumin
serum beta 
2-microglobulin
bone 
marrow
X-ray Lactate 
dehydrogenase
MM  
diagnoses
days of 
chemo
Controls 684 1.20 0.68 0.34 0.05 0.28 0.93 0.27 0.63 3 –
Incident  
cases: 
untreated
54 2.25 1.36 1.12 0.05 0.84 0.88 0.60 0.77 8 –
Prevalent  
cases: 
untreated
18 3.80 1.31 1.00 0.04 0.65 1.03 0.47 0.62 18 –
Incident  
cases: 
treated
182 4.80 2.69 2.23 0.14 1.27 1.67 1.00 2.50 39 240
Prevalent  
cases: 
treated
80 5.37 3.09 3.17 0.09 1.93 0.95 0.67 2.85 34 202
FIgURe 2 | development and validation sample split.
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Multiple myeloma cases had a larger proportion of patients 
with diagnostic tests, more diagnostics tests, a larger proportion 
of the majority of symptoms, and more claims with an MM 
diagnosis code compared with controls up to 180  days prior 
to each index diagnosis. Compared with controls, cases had 
a larger proportion of patients with corticosteroid treatment 
tAbLe 2 | MM symptoms and clinical characteristics around each multiple myeloma diagnosis in the algorithm validation sample.
Controla  
MM diagnoses 
N = 3,185
Cases  
MM diagnoses 
N = 22,419
Case: untreated  
MM diagnoses 
N = 3,442
Case: treated MM 
diagnoses 
N = 18,977
MM diagnoses
MM dx priorb to indexed diagnosis (%) 100.0 100.0 100.0 100.0
Number of MM dx priorb; mean (SD) 8.1 (10.4) 36.7 (29.8) 14.9 (12.7) 40.7 (30.3)
MM dx followingc indexed diagnosis (%) 73.9 99.1 96.0 99.7
Number of MM dx following; mean (SD) 6.9 (10.3) 34.7 (29.1) 12.3 (10.8) 38.8 (29.5)
treatment
Chemo priorb to or on indexed diagnosis (%) 0.0 76.9 0.0 90.8
Chemo followingc indexed diagnosis (%) 0.0 73.5 0.0 86.9
Corticosteroids prior to indexed diagnosis (%) 26.1 71.8 28.3 79.7
Corticosteroids following indexed diagnosis (%) 22.8 61.0 24.4 67.6
symptoms priorb to indexed diagnosis
Monocloncal gammopathy (%) 19.3 11.3 4.1 12.6
Other malignancies (%) 18.6 18.2 12.4 19.2
Anemia diagnosis (%) 29.1 36.1 24.8 38.2
Anemia treatment (%) 13.8 29.8 18.0 31.9
Osteoporosis diagnosis (%) 3.4 1.6 0.9 1.7
Osteoporosis treatment (%) 13.6 60.3 54.2 61.4
Skeletal-related event (%) 9.3 12.6 7.6 13.6
Bone pain/lesions (%) 7.2 9.2 5.0 10.0
Fatigue (%) 9.7 11.5 5.4 12.6
Shortness of breath (%) 7.6 9.8 9.6 9.9
Chest pain (%) 13.8 16.0 14.3 16.3
Peripheral neuropathy (%) 4.8 2.9 3.0 2.9
Renal failure (%) 15.2 21.9 11.1 23.9
Hypercalcemia (%) 1.0 4.9 2.7 5.3
Pneumonia (%) 7.7 7.3 4.6 7.7
Herpes zoster (%) 1.3 2.5 2.1 2.6
Urinary tract/kidney infections (%) 9.1 5.1 6.6 4.8
tests priorb to indexed diagnosis
Urine or serum protein electrophoresis (%) 55.0 70.3 58.8 72.3
Quantitative immunoglobulin levels (%) 39.3 53.7 48.4 54.7
Serum free light chain assay (%) 25.6 44.4 33.5 46.4
Serum albumin (%) 2.3 7.7 2.5 8.7
Serum beta 2-microglobulin (%) 24.3 37.1 31.7 38.1
Bone marrow aspirate or biopsy (%) 46.6 59.8 34.3 64.4
X-ray, skeletal survey/complete (%) 24.1 41.9 28.0 44.5
Lactate dehydrogenase test (%) 28.2 42.6 31.5 44.6
Number of each test; mean (SD)
Urine or serum protein electrophoresis 1.3 (1.7) 3.7 (5.1) 2.2 (2.8) 4.0 (5.4)
Quantitative immunoglobulin levels 0.8 (0.3) 2.2 (3.5) 1.3 (1.8) 2.4 (3.7)
Serum free light chain assay 0.5 (1.0) 1.9 (4.1) 0.8 (1.4) 2.1 (4.3)
Serum albumin 0.0 (0.2) 0.4 (1.9) 0.0 (0.3) 0.5 (2.1)
Serum beta 2-microglobulin 0.4 (0.9) 1.1 (2.2) 0.8 (1.5) 1.1 (2.3)
Bone marrow aspirate or biopsy 0.8 (1.2) 1.1 (1.3) 0.5 (0.9) 1.2 (1.3)
X-ray, skeletal survey/complete 0.3 (0.5) 0.5 (0.7) 0.3 (0.5) 0.5 (0.7)
Lactate dehydrogenase test 0.7 (2.2) 2.6 (5.8) 1.0 (2.0) 2.9 (6.2)
Number of different symptom types (mean, SD) 1.9 (1.8) 2.6 (1.8) 1.9 (1.6) 2.7 (2.0)
Number of different tests types (mean, SD) 2.5 (2.0) 3.6 (2.3) 2.7 (2.2) 3.7 (2.3)
aControl diagnoses are inclusive of (a) MM dx from control population (b) incident case MM dx before they became a case (i.e., prior to the confirmed dx date in the EMR and have 
no chemotherapy for MM).
b180 days prior to indexed diagnosis.
c180 days following indexed diagnosis.
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(72 vs. 26%), anemia treatment with blood transfusion or 
erythropoiesis-stimulating agents (30 vs. 14%), osteoporosis 
treatment with bisphosphonates (60 vs. 14%), renal failure (22 
vs. 15%), anemia diagnoses (36 vs. 29%), and skeletal related 
events (13 vs. 9%) during the 180  days prior to each index 
diagnosis. Additionally, although cases had more claims with a 
MM diagnosis code prior to each index diagnosis (36.7), controls 
still averaged 8.1.
Multiple myeloma untreated cases had similar characteristics 
(tests, symptoms, number of diagnoses) prior to each diagnosis as 
controls. Table 2 presents descriptive results of symptoms, tests, 
treatments, and diagnoses used in the algorithm development 
FIgURe 3 | Algorithm performance results.
6
Princic et al. Algorithm to Identify Multiple Myeloma
Frontiers in Oncology | www.frontiersin.org October 2016 | Volume 6 | Article 224
stratified by MM diagnoses from cases (treated and untreated) 
and controls.
Of 20 algorithms explored in the development sample, the 
baseline algorithm of 2 MM diagnoses and the 3 algorithms 
with highest specificity and sensitivity were run in the validation 
sample. All algorithms started at the earliest MM diagnosis date 
in each patient’s observation window and evaluated the time 
period during the 180 days prior and the 180 days following the 
diagnosis. If the patient did not meet the algorithm requirements 
at the first diagnosis, the next diagnosis was evaluated for inclu-
sion. A patient was flagged by the algorithm at the earliest MM 
diagnosis who met  all requirements. This approach was used 
to maximize the potential for capturing patients as early in the 
diagnostic process as possible.
Three out of the four final algorithms had a PPV over 85%, 
a sensitivity over 80%, and a specificity over 85%. Figure  3 
7Princic et al. Algorithm to Identify Multiple Myeloma
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presents a summary of performance and description for each of 
the algorithms.
The second algorithm had the highest performance (sensitiv-
ity 83%, specificity 94%, and PPV 93%) as its increased complex-
ity lead to improvement in specificity. This algorithm identified 
patients as follows: starting from a MM diagnosis if a patient had 
≥1 additional diagnosis >30 days following the index diagnosis, 
and ≥2 diagnostic tests (or 1 bone marrow test) during the 90 days 
prior to the index diagnosis, and ≥2 additional MM diagnoses 
prior to the tests, or chemotherapy during the 180 days follow-
ing the index diagnosis they were identified as a MM patient. 
Due to the requirement of 2 MM diagnoses prior to diagnostic 
testing, this algorithm may be more likely to select a prevalent 
population and/or a treated population with more symptomatic 
disease. Visual representation of the algorithms validated in this 
analysis is provided in Supplementary Material. Algorithms were 
also tested in the untreated case population separately but no 
notable patterns could be found to differentiate untreated cases 
from controls.
dIsCUssIoN
This study developed and validated three new administrative 
claims-based algorithms with ~10% improvement in PPV over 
the baseline algorithm and prior work (18). Consistent with prior 
work, we found that a combination of multiple diagnoses and 
tests were needed to confirm a MM patient truly has the disease 
(18). Chemotherapy treatment was utilized as an “OR” state-
ment in all three algorithms to improve sensitivity but was not 
a requirement. This method allows for the selection of untreated 
patients providing an opportunity to select incident cases or those 
with SMM. Prior work in the MM population using claims data 
has relied on the selection of a treated population (15, 16). While 
the strategy of requiring both appropriate ICD-9-CM codes and 
the disease-specific treatments can better identify true cases, this 
approach limits the research question to the treated population 
and excludes patients who either are at an early disease stage 
who does not yet require treatment or who forgo treatment for 
personal or medical reasons.
Because earlier treatment of SMM patients may lead to 
improved prognosis, longer survival, and prevent progression to 
symptomatic MM (8, 14), identifying SMM patients is important. 
Our results suggest that developing an algorithm identifying the 
SMM population is challenging given the lack of symptoms and 
treatment, and infrequent testing. SMM cases in this study had 
characteristics very similar to control patients. Incorrect coding 
and lack of using a validated algorithm to select patients is a com-
mon source of misclassification in cancer studies using secondary 
data sources (1). Results from this study support the need for 
validated algorithms in patient selection. Control patients had 
a much higher than expected number of ICD-9-CM diagnosis 
codes for MM during a time period when they were known to 
not have the disease, suggesting that using just one or two claims 
with a diagnosis code is not enough to identify the appropriate 
population.
There are several limitations to this study. Potential meas-
urement error in selection and labeling of cases as incident or 
prevalent is possible since patients appear in EMR systems only 
as long as they visit clinics and have billing records. Care that 
patients receive outside the clinic cannot be captured. These 
challenges of incomplete records and measurement error inher-
ent in EMR databases must be considered when using such 
data. Second, cases and controls were identified by two different 
EMR systems (Oncology and Primary Care), and there may be 
variability in the completeness of data or how information is 
entered and linked across systems. Additionally, the percentage 
of patients flagged in the MarketScan Commercial and Medicare 
databases for the PPV calculations was influenced by the duration 
of time used to identify potential patients. These algorithms 
should be implemented and validated in additional data sources 
to analyze robustness.
Identification of MM prior to the development of symp-
tomatic disease presents a number of challenges due to the 
complex diagnostic process. Using a validated algorithm, such 
as the three presented in this analysis, with adequate sensitivity, 
specificity, and PPV is important when using a secondary 
data source. Each of the algorithms developed and validated 
have strengths (i.e., higher specificity vs. higher sensitivity) 
and variations in complexity that should be considered when 
selecting which one to use for an analysis. Further research is 
needed in additional databases to further investigate identify-
ing patients with SMM. Although the algorithms validated in 
this analysis allow for identification of an incident population, 
they were still more likely to identify patients after symptoms 
appeared.
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